Footnotes

• Correction notice This article has been corrected since it published Online First. The affiliations for the first author have been updated.

• Contributors SD and LP-B planned and wrote the first draft of the paper. ES and MAA critically reviewed the paper. SD and LP-B are guarantors of the article.

• Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

• Disclaimer ES and MAA: the views expressed in this article are primarily those of the authors and do not represent those of the Federal Institute for Drugs and Medical Devices, the Danish Medicines Agency or the European Medicines Agency

• Competing interests SD has served as a speaker, consultant and advisory board member for Schering-Plough, Abbott (AbbVie) Laboratories, Merck and Co, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, α Wasserman, Genentech, Grunenthal, Pfizer, AstraZeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor and Johnson and Johnson. LP-B has received consulting fees from Merck, AbbVie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Therakos, Pharmacosmos, Pilège, BMS, UCB Pharma, Hospira, Celltrion, Takeda, Biogaran, Boerhinger Ingelheim, Lilly, Pfizer, HAC-Pharma, Index Pharmaceuticals, Amgen and Sandoz; and lecture fees from Merck, AbbVie, Takeda, Janssen, Takeda, Ferring, Norgine, Tillots, Vifor, Therakos, Mitsubishi and HAC-Pharma.

• Patient consent for publication Not required.

• Provenance and peer review Not commissioned; externally peer reviewed.

• Data availability statement There are no data in this work.